Atox Bio Company Profile
Established in 2003, Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by an excessive inflammatory response. Atox Bio focuses on novel modulators of the immune response that act broadly to attenuate excessive cytokine responses underlying disease, with therapeutic applications ranging from infectious to inflammatory/autoimmune diseases. These applications represent areas with major unmet medical need.
News Articles
Atox Bio to seek funds by year-end for more trials
TEL AVIV (Reuters) - Israeli biotechnology firm Atox Bio, developing a drug it hopes can treat severe infections such as those caused by flesh-eating bacteria and deadly viruses, expects to ask invest...
FDA to fast track Atox Bio's flesh-eating bacteria treatment
TEL AVIV, Sept 10 (Reuters) - Israeli biotechnology firm Atox Bio said the U.S. Food and Drug Administration has granted fast track designation to AB103, its product in development for the treatment o...
Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as "flesh eating bacteria" demonstrating that administration of a single dose of AB103, given...
Atox eyes more money to develop drug for severe infections
Atox Bio aims to raise more funds from investors this year to develop an experimental treatment for severe infections such as -More-
Atox Bio Announces Positive Top Line Results in the AB103 Necrotizing Soft Tissue Infections ...
Top line results demonstrate meaningful improvement across multiple end points AB103 was shown to be very well tolerated by patients
Israel Firm Seeks Funding For More Trials Of Flesh-Eating Bacteria Drug
Israel's Atox Bio plans a fund-raising effort to cover the expense of more Phase II trials of its drug to treat severe infections of flesh-eating bacteria and deadly viruses.
Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U....
Atox Bio today reported positive top-line results from the AB103 randomized, double-blind, placebo-controlled Phase 2a trial in patients with Necrotizing Soft Tissue Infections (N...
Drugs and Medications
None
PubMed Articles
Chaperones CCS, ATOX and COXIV responses to copper supplementation in healthy adults.
Assessment of proteins in blood and other tissues has failed to identify markers of early copper effects on health. Studies in animal models show that chaperone of SOD (CCS) respond to changes of copp...
Clinical Trials
None
Companies
Established in 2003, Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by an excessive inflammatory response. Atox Bio focuses on...
More Information about "Atox Bio" on BioPortfolio
We have published hundreds of Atox Bio news stories on BioPortfolio along with dozens of Atox Bio Clinical Trials and PubMed Articles about Atox Bio for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atox Bio Companies in our database. You can also find out about relevant Atox Bio Drugs and Medications on this site too.
